TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22674612
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 on day 1, every 3 weeks)
Study: 15064218
Drug: Physician-administered intervention
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-administered intervention
Study: 11447379
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg twice daily for 3 days)
Study: 8064166
Drug: Captopril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (1 mg/kg, oral)
Study: 8064166
Drug: Remikiren (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (1 mg/kg, intravenous infusion over 60 min)
Study: 1932670
Drug: High-dose terlipressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose terlipressin
Study: 1932670
Drug: Low-dose terlipressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose terlipressin
Study: 6119724
Drug: Melperone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone 10 mg
Study: 6119724
Drug: Melperone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone 25 mg
Study: 6119724
Drug: Melperone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone 50 mg
Study: 6119724
Drug: Thioridazine 10
Normalized name: thioridazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 10 mg
Study: 6119724
Drug: Thioridazine 25
Normalized name: thioridazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 25 mg
Study: 6119724
Drug: Levomepromazine 10
Normalized name: Lévomépromazine
DrugBank: Methotrimeprazine (DB01403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomepromazine 10 mg
Study: 6119724
Drug: Levomepromazine 25
Normalized name: Lévomépromazine
DrugBank: Methotrimeprazine (DB01403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomepromazine 25 mg
Study: 6119724
Drug: Levomepromazine 50
Normalized name: Lévomépromazine
DrugBank: Methotrimeprazine (DB01403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomepromazine 50 mg
Study: 6119724
Drug: Chlorprotixene 10
Normalized name: Chlorprotixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorprotixene 10 mg
Study: 6119724
Drug: Chlorprotixene 25
Normalized name: Chlorprotixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorprotixene 25 mg
Study: 6119724
Drug: Chlorprotixene 50
Normalized name: Chlorprotixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorprotixene 50 mg
Study: 29193937
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tamsulosin and Oxybutynin
Study: 25549690
Drug: Computer-based phoneme-discrimination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based phoneme-discrimination training (twice a week for three weeks)
Study: 15157690
Drug: 10 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg.kg(‐1) body weight caffeine
Study: 15157690
Drug: 5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg.kg(‐1) body weight caffeine
Study: 11307042
Drug: Ro 41-3696
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 41-3696 at 10 mg
Study: 11307042
Drug: Ro 41-3696
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 41-3696 at 3 mg
Study: 11307042
Drug: Ro 41-3696
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 41-3696 at 5 mg
Study: 11307042
Drug: Ro 41-3696
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 41-3696 at 1 mg
Study: 7805371
Drug: Gestodene 75
Normalized name: ethinyl estradiol 30 MCG / gestodene 75 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestodene 75 mcg plus ethinyl estradiol 30 mcg
Study: 7805371
Drug: Desogestrel 150
Normalized name: Desogestrel 150 microgram and ethinylestradiol 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 150 mcg plus ethinyl estradiol 30 mcg
Study: 3280000
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CyA) at a mean dose of 5.5 mg/kg/day
Study: 3280000
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CyA) at a mean dose of 5.6 mg/kg/day
Study: 3280000
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (CyA) at a lower mean dose of 3 mg/kg/day during tapering off phase
Study: 3280000
Drug: CyA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA treatment
Study: 28555959
Drug: Spironolactone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5 mg with eventual escalation to 25 mg daily over a 4-week period)
Study: 24455542
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (66 Gy in 33 fractions, 5 fractions/week, with concomitant chemotherapy - Cisplatin 30 mg/m² IV once weekly for 6 weeks)
Study: 24455542
Drug: Arm C
Normalized name: Forearm Crutch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C (30 Gy in 15 fractions followed by 1.4 Gy twice daily for 15 days, total 72 Gy in 6 weeks)
Study: 21526444
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose transdermal nicotine (21/14 mg for men/women)
Study: 21526444
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose transdermal nicotine (7 mg)
Study: 12652326
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg bolus plus a maintenance infusion)
Study: 12652326
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous digoxin (13 mcg/kg)
Study: 10751074
Drug: Once-weekly rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-weekly rifapentine + isoniazid (HRp1)
Study: 10751074
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly isoniazid + rifampicin (HR3)
Study: 8609830
Drug: Adjuvant recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant recombinant human growth hormone (rhGH) treatment (0.15 mg/kg/d)
Study: 1575820
Drug: bezafibrate 600
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 600 mg/day
Study: 30232699
Drug: Bisoprolol-Amlodipine 5
Normalized name: perindopril, bisoprolol, amlodipine and indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet
Study: 30232699
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet (Control)
Study: 27634471
Drug: Robot Gym
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot Gym therapy (technology-assisted rehabilitation)
Study: 22308241
Drug: COGRAT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: COGRAT (Cognitive therapy + Graded activity training)
Study: 22308241
Drug: CO (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO (Cognitive therapy only)
Study: 20736151
Drug: Maraviroc +
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc + Optimized Background Therapy (OBT)
Study: 20736151
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Optimized Background Therapy (OBT)
Study: 17585116
Drug: Erythromycin 2
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 2 days + midazolam (2.5 mg) (EM2)
Study: 17585116
Drug: Erythromycin 4
Normalized name: erythromycin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 4 days + midazolam (2.5 mg) (EM4)
Study: 17585116
Drug: Erythromycin 7
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 7 days + midazolam (2.5 mg) (EM7)
Study: 17585116
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg) without erythromycin (EM0)
Study: 12227708
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg/day) for 6 months
Study: 10509849
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once daily for nonulcer patients, 20 mg twice daily for ulcer patients for 14 days) plus two antimicrobials (amoxicillin, clarithromycin or roxithromycin, metronidazole, ornidazole, or tinidazole for 10 days)
Study: 7760866
Drug: Six weeks
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six weeks of oral anticoagulant therapy (warfarin or dicumarol)
Study: 7760866
Drug: Six months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six months of oral anticoagulant therapy (warfarin or dicumarol)
Study: 2179082
Drug: D,L-Kavain (Neuronika)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-Kavain (Neuronika)
Study: 27933512
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine treatment (Zuogui Pill and Yougui Pill for low risk; Qingwen Baidu Decoction and Bazhen Decoction for moderate risk; Gexia Zhuyu Decoction and Qinghao Biejia Decoction combined with Shiquan Dabu Decoction for high risk)
Study: 21067823
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine hydrochloride (20 mg/ml) with 0.00125% epinephrine
Study: 21067823
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% bupivacaine hydrochloride
Study: 15459217
Drug: R115777 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: R115777 (300 mg twice daily)
Study: 9540015
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet plus exercise
Study: 9540015
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (diet, exercise, combination)
Study: 8210250
Drug: MST-16 at
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST-16 at 1,600 mg/body for 5 consecutive days repeating every 4 weeks
Study: 8210250
Drug: MST-16 at
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST-16 at 1,200 mg/body for 10-14 consecutive days every 5 weeks
Study: 8210250
Drug: MST-16 at
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST-16 at 1,200 mg/body daily for at least 4 weeks
Study: 8210250
Drug: MST-16 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST-16 (all doses)
Study: 22216522
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg and 200 mg daily)
Study: 22216522
Drug: Practolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (200 mg and 400 mg daily)
Study: 30413829
Drug: Non-pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological therapy
Study: 25398967
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Vitamin D3 (1000 mg/d of calcium plus 400 IU/d of vitamin D3)
Study: 23514701
Drug: TMP transdermal
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMP transdermal patch
Study: 23514701
Drug: TMP oral
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMP oral tablets (TMPP)
Study: 16924336
Drug: Passive topical
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive topical application of Carisolv + SRP
Study: 16924336
Drug: Active topical
Normalized name: Similasan Arnica Active Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active topical application of Carisolv + SRP
Study: 16924336
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Carisolv + SRP + 24% EDTA
Study: 14714579
Drug: Imidapril (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5‐10 mg/day) or benazepril (10‐20 mg/day) for 6 weeks
Study: 10986059
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy including multiple, prolonged courses of corticosteroid (dexamethasone)
Study: 3534246
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment over 12 weeks (6-week standard trial followed by 6-week continuation for responders)
Study: 31547949
Drug: Splint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint therapy with ultrasound‐guided arthrocentesis
Study: 31547949
Drug: Splint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint therapy with low‐level laser therapy
Study: 20565314
Drug: Unit-dose pipettes
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unit-dose pipettes
Study: 18391094
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care treatment with chlorthalidone and atenolol (n=2365)
Study: 12866040
Drug: Aspirin exclusively
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin exclusively
Study: 12866040
Drug: Non-aspirin NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin NSAIDs exclusively (e.g., ibuprofen)
Study: 12866040
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin and non-aspirin NSAIDs
Study: 12866040
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of aspirin or other non-aspirin NSAIDs
Study: 10819336
Drug: Zanamivir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (10 mg, inhaled, twice daily for 5 days)
Study: 8887036
Drug: Glycyrrhizin (GL)
Normalized name: glycyrrhizinate
DrugBank: Glycyrrhizic acid (DB13751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycyrrhizin (GL) given intravenously at a dose of 40 ml (0.2% solution) daily for 4 consecutive weeks.
Study: 24858506
Drug: Forest therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forest therapy (viewing a real forest landscape for 15 min)
Study: 19853510
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1-4, 9-12, and 17-20 of a 28-day cycle (high dose)
Study: 19853510
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1, 8, 15, and 22 of a 28-day cycle (low dose)
Study: 19853510
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone group
Study: 19853510
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone group
Study: 6781586
Drug: High-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose regimen
Study: 19853510
Drug: Low-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose regimen
Study: 16197655
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg/day increasing to 100 mg/day after 1 week)
Study: 14499730
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and heparin
Study: 8707167
Drug: Standard unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unfractionated heparin (Ca-heparin, 3 x 5,000 U)
Study: 1867903
Drug: Contract condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contract condition with co-worker-delivered reminders, prompting at least once a month for six months, plus mailed prompts monthly.
Study: 1867903
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition with mailed prompts monthly.
Study: 25647757
Drug: R-L+ stimulation
Normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-L+ stimulation (anodal stimulation of left PPC)
Study: 25647757
Drug: R+L- stimulation
Normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R+L- stimulation (anodal stimulation of right PPC)
Study: 10990103
Drug: Enteral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral plus parenteral nutrition (treatment group)
Study: 8741021
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (240 mg daily)
Study: 1331493
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 200 mg kg‐1
Study: 1331493
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 300 mg kg‐1
Study: 1331493
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 400 mg kg‐1
Study: 1331493
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 500 mg kg‐1
Study: 1331493
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 100 mg kg‐1
Study: 1331493
Drug: Placebo (CaCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (CaCO3 500 mg kg‐1)
Study: 4019271
Drug: Delayed 252Cf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed 252Cf implant therapy
Study: 4019271
Drug: Early 252Cf
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early 252Cf implant therapy
Study: 31115845
Drug: Participants in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the SELECT BC trial receiving either S-1 or taxane as first-line treatment.
Study: 31115845
Drug: Non-participants who
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-participants who received the same chemotherapy (S-1 or taxane) after declining participation.
Study: 26636418
Drug: P‐3074 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐3074 1 mL (2.275 mg) applied to the scalp once a day (o.d.)
Study: 26636418
Drug: P‐3074 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐3074 1 mL (2.275 mg) applied to the scalp twice a day (b.i.d.)
Study: 26636418
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral tablet of finasteride once a day (o.d.)
Study: 24484178
Drug: rF-B7.1 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: rF-B7.1 or rF-TRICOM (3.7×10(7) or 3.7×10(8) plaque-forming units) administered by intralesional injection every 4 weeks
Study: 19857185
Drug: Therapeutic cancer
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cancer vaccines (various types including antigen-presenting-cell-based, vector-based, and whole tumor cell vaccines)
Study: 16094110
Drug: Topical lysine-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lysine-aspirin (16 mg every 48 hours for 6 months)
Study: 7564036
Drug: Warfarin (anticoagulant)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (anticoagulant) alone for 21 days
Study: 7564036
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of anticoagulants and antiplatelet agents
Study: 1793024
Drug: Gold treatment
Normalized name: GLYCERIN 0.01 g in 1 mL TOPICAL LIQUID [BURZANGMURY GOLD TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold treatment
Study: 1793024
Drug: Both gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both gold and MTX treatment
Study: 31782786
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucocorticoids (GCs) and cyclophosphamide (CYC)
Study: 31474526
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care practitioner counseling on medication disposal
Study: 22926533
Drug: Oxygen pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen pressure injection (OPI) device during MAL‐PDT
Study: 17699970
Drug: 750 ml
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 ml spacer with valve
Study: 17699970
Drug: 165 ml
Normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 ml spacer with valve
Study: 17699970
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml spacer without valve
Study: 17699970
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml indigenously made spacer without valve
Study: 17699970
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml indigenously made spacer without valve
Study: 15601653
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine followed by oral Malarone
Study: 15601653
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine followed by oral quinine
Study: 6775518
Drug: High nitrogen
Normalized name: Isosource High Nitrogen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrogen (N) intravenous nutritional regimen
Study: 26969422
Drug: Metal injection
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal injection moulding (MIM) brackets